Patient Selection and Efficacy Across Global Studies

Dr. Chieh-Lung Cheng addresses where BTK inhibitors fit in relapsed/refractory PCNSL and how he selects patients, noting that in Taiwan tirabrutinib is used as monotherapy rather than in combination. He summarizes efficacy across the Japanese Phase 1/2 study, the U.S. PROSPECT Phase 2 study presented at ASCO, and Taiwan's real-world REVEAL observational study presented at EHA, describing consistently high response rates and durable responses in a meaningful subset of patients. He characterizes tirabrutinib monotherapy as effective across diverse ethnic populations, age groups, and lines of therapy, and now a leading option for relapsed/refractory PCNSL in Taiwan. He also flags its limitations, including a relatively short median progression-free survival and drug-related adverse events such as skin rash and neutropenia requiring careful monitoring, reiterating that only monotherapy, not combination, is approved and reimbursed in Taiwan.